Tirzepatide denied as non-formulary by Cigna?

T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

## Cigna Non-Formulary Denial of Tirzepatide — The Express Scripts Tier Mechanic

A non-formulary denial of tirzepatide (Mounjaro/Zepbound) from Cigna is a formulary-tier exclusion, not a clinical denial — and that distinction dictates the entire appeal strategy. Cigna pharmacy benefits are administered by Express Scripts/Evernorth, and the denial letter will typically reference exclusion from the Cigna Standard, Performance, or Value 3-Tier/4-Tier formulary, often citing Coverage Policy IP0532 (Mounjaro/Zepbound — GLP-1/GIP Receptor Agonists) and the relevant National Preferred Formulary (NPF) bulletin. For 2026, Express Scripts has continued to push GLP-1/GIP agents onto restrictive utilization-management tracks, and Cigna's CNF-749 rule requires documented T2DM with HbA1c ≥6.5% (consistent with ADA Standards of Care §2) for Mounjaro coverage — Zepbound for obesity sits on an entirely separate exclusion track tied to employer-group rider election.

The first procedural lever is the formulary exception request under 42 CFR §423.578(b) (if Medicare Part D via Cigna Healthcare Medicare) or, for commercial ERISA plans, the plan's formulary exception process disclosed under 29 CFR §2560.503-1(g). Express Scripts requires the prescriber to submit the exception via the Evernorth/ESI Coverage Determination line (1-800-753-2851) or the electronic CoverMyMeds/SureScripts portal — not the medical-benefit appeal address on the EOB. Filing through the wrong channel restarts the clock and is the most common procedural failure.

The clinical packet must show: (1) confirmed T2DM diagnosis with ICD-10 E11.x, (2) HbA1c ≥6.5% within 90 days (CNF-749 hard requirement), (3) documented intolerance, contraindication, or inadequate response to formulary-preferred GLP-1s — typically semaglutide (Ozempic) and dulaglutide (Trulicity) on the Cigna NPF — and (4) a clinical rationale why tirzepatide's dual GIP/GLP-1 mechanism is medically necessary versus the preferred mono-agonists (SURPASS-2 head-to-head data showing superior A1c reduction is the cleanest citation).

For step-therapy override, invoke 29 USC §1185d (Consolidated Appropriations Act step-therapy protections) and state-law analogues — Texas Insurance Code §1369.0546, California Health & Safety Code §1367.206, and New York Insurance Law §4903 all require expedited override when continuation of preferred therapy would cause harm or has already failed. If the denial reads as a behavioral or NQTL parity issue (rare for GLP-1s but possible if comorbid binge-eating disorder is documented), layer in 29 CFR §2590.712 parity arguments.

If Cigna upholds the internal appeal, escalate to external review under 45 CFR §147.136 within 4 months — IROs reverse Cigna formulary-exception denials at a notably high rate when the SURPASS trial data and documented preferred-agent failure are in the record.

Tactical tip: Pull the exact Coverage Policy IP0532 PDF from Cigna's provider portal and quote the medical-necessity criteria verbatim in your letter — Express Scripts reviewers are trained to pattern-match against their own policy language, and verbatim citation moves the file to clinical pharmacist review faster than a narrative rebuttal.